BRPI0919690A2 - métodos para detectar células-tronco de tumor em um paciente, para monitorar o efeito do tratamento de um tumor em um paciente, e para radioterapia em um paciente com câncer, formulaçõ farmacêutica, e, composto - Google Patents

métodos para detectar células-tronco de tumor em um paciente, para monitorar o efeito do tratamento de um tumor em um paciente, e para radioterapia em um paciente com câncer, formulaçõ farmacêutica, e, composto

Info

Publication number
BRPI0919690A2
BRPI0919690A2 BRPI0919690A BRPI0919690A BRPI0919690A2 BR PI0919690 A2 BRPI0919690 A2 BR PI0919690A2 BR PI0919690 A BRPI0919690 A BR PI0919690A BR PI0919690 A BRPI0919690 A BR PI0919690A BR PI0919690 A2 BRPI0919690 A2 BR PI0919690A2
Authority
BR
Brazil
Prior art keywords
patient
tumor
radiotherapy
treating
monitoring
Prior art date
Application number
BRPI0919690A
Other languages
English (en)
Portuguese (pt)
Inventor
Alan Cuthbertson
Peter Brian Iveson
Rajiv Bhalla
Vijajaya Raj Kuniyil Kulangara
Original Assignee
Ge Healthcare Ltd
Gen Electric
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd, Gen Electric filed Critical Ge Healthcare Ltd
Publication of BRPI0919690A2 publication Critical patent/BRPI0919690A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRPI0919690A 2008-10-21 2009-10-20 métodos para detectar células-tronco de tumor em um paciente, para monitorar o efeito do tratamento de um tumor em um paciente, e para radioterapia em um paciente com câncer, formulaçõ farmacêutica, e, composto BRPI0919690A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10700108P 2008-10-21 2008-10-21
GBGB0819280.9A GB0819280D0 (en) 2008-10-21 2008-10-21 Imgaing and radiotherapy methods
PCT/US2009/061271 WO2010048144A2 (en) 2008-10-21 2009-10-20 Imaging and radiotherapy methods

Publications (1)

Publication Number Publication Date
BRPI0919690A2 true BRPI0919690A2 (pt) 2015-12-08

Family

ID=40097766

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919690A BRPI0919690A2 (pt) 2008-10-21 2009-10-20 métodos para detectar células-tronco de tumor em um paciente, para monitorar o efeito do tratamento de um tumor em um paciente, e para radioterapia em um paciente com câncer, formulaçõ farmacêutica, e, composto

Country Status (12)

Country Link
US (1) US20110286922A1 (enExample)
EP (1) EP2349351A2 (enExample)
JP (1) JP2012506439A (enExample)
KR (1) KR20110074988A (enExample)
CN (1) CN102186505A (enExample)
AU (1) AU2009307783A1 (enExample)
BR (1) BRPI0919690A2 (enExample)
CA (1) CA2738955A1 (enExample)
GB (1) GB0819280D0 (enExample)
MX (1) MX2011004161A (enExample)
RU (1) RU2011113996A (enExample)
WO (1) WO2010048144A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
CU23844B1 (es) * 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
SI3708192T1 (sl) * 2009-06-12 2023-12-29 Cellectar, Inc. Eter fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic
EP2515949A1 (en) * 2009-12-22 2012-10-31 GE Healthcare UK Limited Aldehydes for in vivo imaging of aldh in cancer stem cells
WO2012074840A2 (en) * 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
WO2013012754A1 (en) * 2011-07-15 2013-01-24 University Of Southern California Boron-based dual imaging probes, compositions and methods for rapid aqueous f-18 labeling, and imaging methods using same
WO2013048832A1 (en) * 2011-09-29 2013-04-04 Ge Healthcare Limited 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells
WO2013048811A1 (en) * 2011-09-30 2013-04-04 Ge Healthcare Limited Imaging and radiotherapy methods for tumour stem cells
US8927732B2 (en) * 2012-03-30 2015-01-06 General Electric Company Biotin stannane for HPLC-free radioiodination
WO2014145493A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
EP3450963A4 (en) * 2016-04-28 2020-01-29 National University Corporation Nagoya University FLUORESCENT PROBE, METHOD FOR DETECTING FLUORESCENCE AND METHOD OF USING FLUORESCENT PROBE
FR3054564B1 (fr) * 2016-07-28 2018-08-31 Advanced Biodesign Substrat specifique d'une isoenzyme de l'aldh
KR101941223B1 (ko) * 2017-04-04 2019-01-22 을지대학교 산학협력단 복강경 수술용 삼중 융합영상장치
JP2023025307A (ja) * 2020-01-31 2023-02-22 国立大学法人 東京大学 アルデヒドロゲナーゼ１ａ１検出用青色蛍光プローブ

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
WO2003093498A1 (en) * 2002-04-29 2003-11-13 The Ohio State University Inhibition of protein tyrosine phosphatases and sh2 domains by a neutral phosphotyrosine mimetic
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0502277D0 (en) * 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
US20080058316A1 (en) * 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
WO2008036419A2 (en) * 2006-09-22 2008-03-27 The Regents Of The University Of Michigan Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker

Also Published As

Publication number Publication date
JP2012506439A (ja) 2012-03-15
WO2010048144A3 (en) 2010-07-22
WO2010048144A2 (en) 2010-04-29
EP2349351A2 (en) 2011-08-03
MX2011004161A (es) 2011-06-06
US20110286922A1 (en) 2011-11-24
RU2011113996A (ru) 2012-11-27
CN102186505A (zh) 2011-09-14
CA2738955A1 (en) 2010-04-29
KR20110074988A (ko) 2011-07-05
GB0819280D0 (en) 2008-11-26
AU2009307783A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
BRPI0920847A2 (pt) composto, formulação farmacêutica, e, método para o tratamento, prevenção ou retardo na progressão de câncer em um paciente
BR112013000745A2 (pt) "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo"
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
IL220040A0 (en) Methods and low dose regimens for treating red blood cell disorders
BR112013004458A2 (pt) método e kit para detectar a presença de células que expressam he-4 em um indivíduo humano, e, método para o monitoramento de eficácia de tratamento de um paciente de câncer humano
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013033940A2 (pt) terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
PT2470199T (pt) Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida
BR112015011271A2 (pt) cortina medicinal, sistema para o tratamento de um tecido local com a pressão reduzida, método para fabricar uma cortina medicinal, e método para o tratamento de um tecido local com a pressão reduzida
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0819453A2 (pt) Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
BRPI1007602A2 (pt) "anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BRPI0814776A2 (pt) Método para manter consistência para tratamentos de distribuição de droga em aerossol, e, aparelho para distribuição de droga em aerossol
BRPI0811845A2 (pt) Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
BR112014003997A2 (pt) composto, método para inibição da atividade de pak1 em uma célula e paciente, método para o tratamento ou melhoria da gravidade do câncer ou de um distúrbio hiperproliferativo em um paciente, utilização do composto e composição
DE602007000788D1 (de) Vielblattkollimator und Strahlentherapieanlage
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112012000417A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético
ZA200905703B (en) Specific therapy and medicament using integrin ligands for treating cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.